30 results
Primary objective: to define the maximal tolerated dose (MTD) of Olaparib in combination with high dose radiotherapy with and without daily dose cisplatin in locally advanced non-small cell lung carcinoma.
To investigate the influence of short implants (6 mm in length) on marginal peri-implant bone levels, clinical variables and patient satisfaction.
To investigate the influence of platform-switched implant-abutment connections (smaller diameter abutment on wider diameter implant) of short implants (8.5 mm in length) on marginal peri-implant bone levels and clinical variables.
The primary objective of this study is to investigate the improvement of masticatory function of implant-supported RPD treatment in free-ending, bilateral mandibular partial edentulism. The secondary objectives include patient satisfaction (OHIP14…
The aim of this study to evaluate the clinical performance of short implants (4 mm in length) in the resorbed posterior mandibular region of partially edentulous patients that will be restored with a single crown.
To investigate the influence of different implant neck designs on marginal peri-implant bone levels and clinical variables.
• To evaluate the effect of olaparib on exposure to anastrozole by determination of steady-state exposure to anastrozole in the presence and absence of steady-state exposure to olaparib• To evaluate the effect of anastrozole on exposure to olaparib…
To perform a pilot study to determine the feasibility of conducting a two-arm phase I trial and to determine the recommended dose level for phase II (RP2D) study and assess the safety of the combination olaparib and melphalan in patients with…
To define the maximal tolerated dose (MTD) of olaparib in combination with radiotherapy in laryngeal and oropharyngeal SCC.
The primary purpose of the study is to determine the efficacy of AZD2281 compared to placebo in serous ovariancancer platinum sensitive patients and in a defined HRD subset.
This research study is designed to check whether olaparib is also effective in treating ovarian cancer which does not have a germline deleterious BRCA mutation, and whether olaparib causes any side effects.A tablet formulation of olaparib is being…
To assess the safety and tolerability of adjuvant treatment with olaparib
Part 1: Determine the Recommended Phase II Dose
To define the maximal tolerated dose (MTD) of olaparib in combination with radiotherapy of the breast and regional lymph nodes in patients with breast cancer without the use of skin bolus (arm A) or with the use of skin bolus (arm B).
Primary objective: To determine the efficacy of the combination of olaparib and abiraterone vs placebo and abiraterone by assessment of rPFS (Radiographic progression-free survival) in patients with mCRPC (Metastatic castration-resistant prostate…
To determine the efficacy (as assessed by rPFS) and safety of olaparib versus investigator choice of enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal…
The aim of the study is comparison of two and four dental implants supporting an overdenture in the upper jaw for patients who experience problems with retention and stability of the upper denture.
Based on results from a comparative review (Paoletti 2013), we hypothesize that if the toxicity profile and the PK parameters observed in children treated at the adult RP2D are similar to those in adults; escalating to the MTD is not necessarily…
Primary: To determine whether the outcome of the RAD51 assay (HR proficient or HR deficient) correlates with objective response rate (RR) of olaparib, in patients with recurrent high grade epithelial ovarian cancer.Secondary:• Compare the…
Thel aim of this project is to analyse hybrid implants placed in de posterior mandible of periodontally compromised patients and to compare the treatment outcome of either moderate rough or hybrid implants.